Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of veliparib when given together
with cisplatin and vinorelbine ditartrate in treating patients with breast cancer that has
returned or spread to other parts of the body. Veliparib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
cisplatin and vinorelbine ditartrate, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving veliparib together with combination chemotherapy may be a better treatment
for breast cancer.